#protara
LightNews LightNews
ambabheg.bsky.social
1365 Challenge No. 1 - 2026 publish daily old unpublished pics
Day 125 - Sunset behind the Protara, Naxos, Greece 2011
#fotosbyfaj #faj365challenge2026 #photography #blueskykin
#naxos #sunset #protara #greece
More at fotosbyfaj.com
The Portara on Naxos silhouetted against a warm Aegean sunset, with the sun glowing behind the massive stone doorway and soft orange light reflecting across the sea.
May 6, 2026 at 6:07 AM
blueresearch.bsky.social
Protara Therapeutics management to meet with Cantor
Reported Thursday, Oct 8 - 4:47pm EDT (TheFly subscription required to read more.)
thefly.com
October 8, 2026 at 8:50 PM
marketwirenews.com
Just In: ( NASDAQ: #TARA ) Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

#StockMarket #News
October 21, 2024 at 4:50 PM
worldfood.bsky.social
🇨🇾 Κύπρος - Kıbrıs
🍽️ Hippocampus Lounge Restaurant
📍 Hippocampus, 18, Leoforos Protara, Πρωταράς, Παραλίμνι, Δήμος Παραλιμνίου - Δερύνειας, Επαρχία Αμμοχώστου, Κύπρος, 5296, Κύπρος - Kıbrıs

🔗 View on Google Maps
Food at Hippocampus Lounge Restaurant in Κύπρος - Kıbrıs
May 16, 2026 at 9:10 AM
pdrworld.bsky.social
Bladder Cancer treatment is such a puzzle - the quixotic reliance on the magic on Bacillus coupled with the modern technology of bladder instillation. After a long lull, new therapeutics are here. @bymadeleinea.bsky.social tells the story: www.oncologypipeline.com/apexonco/pro...
Protara could take on J&J
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
www.oncologypipeline.com
December 7, 2024 at 2:04 PM
stockquakes.com
#Trading #StockMarket

Stock Premarket - Dec 03, 2025

See StockQuakes.substack.com

UP
↑ CLNN Clene Inc. 39.2%
↑ PMAX Powell Max LTD 30.0%
↑ KXIN Kaixin Holdings 25.3%
↑ IRBT Irobot Corp 21.5%
↑ TARA Protara Therapeutics, Inc. 18.0%
↑ SMX Smx (Security Matters) Pub... 17.8%
StockQuakes | StockQuakes Team | Substack
Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with hundreds of subscribers.
StockQuakes.substack.com
December 3, 2025 at 2:06 PM
prismmarketview.bsky.social
#$TARA
Protara Therapeutics, Inc. reported Q2 2026 financial results with $161.9 million in cash funding operations into 2028, while outlining 4Q 2026 milestones across its TARA-002 and IV Choline Chloride (THRIVE-3) programs.
prismmarketview.com/companies/pr...
Protara Therapeutics, Inc.
Headquartered in New York City, Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for canc
prismmarketview.com
August 11, 2026 at 6:52 PM
blueresearch.bsky.social
Protara Therapeutics reports Q2 EPS (36c), consensus (31c)
Reported Tuesday, Aug 11 - 8:08am EDT (TheFly subscription required to read more.)
thefly.com
August 11, 2026 at 12:10 PM
stocktitan.net
#TARA Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

https://www.stocktitan.net/news/TARA/protara-therapeutics-announces-second-quarter-2026-financial-results-uwckga8w0mgj.html
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary
www.stocktitan.net
August 11, 2026 at 12:00 PM
gunpowderusa.bsky.social
⚠️ $TARA Protara Therapeutics / Cash Runway: Cash and equivalents fell 66% from $49.7M to $17.1M in just six months. At the current H1 2026 operating cash burn rate of $36.7M, the company has less than six months of liquidity without further financing or d...
August 11, 2026 at 2:35 PM
quant-hub.bsky.social
🚨 $TARA
On August 11, 2026, Protara Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
SEC Filing: TARA
Click to view the official SEC document.
www.sec.gov
August 11, 2026 at 12:06 PM
nicemagazine.bsky.social
Φενέρμπαχτσε – Dubai BC 69-93: Η πρωτάρα στην Euroleague διέσυρε την πρωταθλήτρια μέσα στην Πόλη

https://nicemagazine.gr/fenerbachtse-dubai-bc-69-93-i-protara-stin-euroleague-di/
October 15, 2025 at 12:29 AM
notreload.bsky.social
#$TARA +2% [JPMorgan starts coverage on Protara Therapeutics with Overweight rating and $27 PT. TARA-002, a de-risked Picibanil replica, targets NMIBC bladder cancer and lymphatic malformations with strong clinical backing from Japan/Taiwan.] notreload.xyz/jpmorgan-bet...
JPMorgan Initiates Overweight on Protara (TARA) at $27
JPMorgan starts coverage on Protara Therapeutics with Overweight rating and $27 PT. TARA-002, a de-risked Picibanil replica, targets NMIBC bladder cancer and lymphatic malformations with strong clinic...
notreload.xyz
March 4, 2026 at 11:54 AM
notreload.bsky.social
$REGN +2%, $ERAS +2.75%, $TARA +3.5%, $DSGN +6%, $ORIC +4.3% [Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.]
Biotech Upgrades: Regeneron, Erasca, TARA, DSGN, ORIC
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pi...
notreload.xyz
January 7, 2026 at 2:26 PM
notreload.bsky.social
$TARA -20.5% [Protara raised $75 million via a stock sale to fund clinical trials, mainly for TARA-002, a treatment for bladder cancer and rare lymphatic issues. The company's stock dropped 20% following the discounted pricing announcement.] ir.protaratx.com/news-release...
December 5, 2025 at 4:31 PM
notreload.bsky.social
$TARA +8% [Protara Therapeutics stock jumped after positive Phase 2 interim results showed strong response rates for TARA-002 in non-muscle invasive bladder cancer patients.] notreload.xyz/protara-shar...
Protara Shares Rise on Trial Results
Protara Therapeutics stock jumped after positive Phase 2 interim results showed strong response rates for TARA-002 in non-muscle invasive bladder cancer patients.
notreload.xyz
December 3, 2025 at 7:22 PM
pressreleasecc.com
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical
www.pressreleasecc.com
April 10, 2026 at 5:45 AM
nasdaq.activitypub.awakari.com.ap.brid.gy
Analysts Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $21.40 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) have earned a consensus recommendation of “Moderate Buy...

#Banking #Consensus #Rating #Articles

Origin | Interest | Match
Analysts Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $21.40
Shares of Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation […]
www.tickerreport.com
April 4, 2026 at 6:23 AM
nasdaq.activitypub.awakari.com.ap.brid.gy
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Buy” by Brokerages Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) has been assigned a consensus recommendation of...

#Banking #Consensus #Rating #Articles

Origin | Interest | Match
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of “Buy” by Brokerages
Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target […]
www.tickerreport.com
September 18, 2025 at 7:50 AM
item502.eyesec.it
Protara Therapeutics, Inc. (0001359931) (Filer) (cik: 0001359931) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1359931/000121390026073184/0001213900-26-073184-index.htm
June 29, 2026 at 9:24 PM
stocknear.bsky.social
$TARA Protara Therapeutics shares are trading lower. The company announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002
April 28, 2025 at 4:38 PM
stocknear.bsky.social
$TARA Protara Therapeutics shares are trading higher after the company announced it will review the interim data from its Phase 2 ADVANCED-2 trial.
April 23, 2025 at 2:15 PM
dekmartrades.bsky.social
$TARA Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC foxrunner.com?fpr=newsscan...
December 5, 2024 at 12:03 PM
longtail-news.bsky.social
Feed: "Endpoints News"
By: ENDPOINTS on Friday, December 5, 2025
Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara
Plus, news about Vanda, Hangzhou Highlightll Pharmaceutical and Guard Therapeutics.
endpoints.news
December 5, 2025 at 11:34 PM
longtail-news.bsky.social
Feed: "Clinical Trials Arena"
By: sdebbarma on Thursday, November 20, 2025
Protara announces encouraging TARA-002 Phase II study data
Protara Therapeutics has announced encouraging interim data from its ongoing Phase II STARBORN-1 study evaluating TARA-002 in paediatric subjects with LMs.
www.clinicaltrialsarena.com
November 21, 2025 at 4:28 AM